Milsaperidone is an active metabolite of iloperidone ...

Vanda Pharmaceuticals is riding a regulatory roller coaster over the last few months. | Vanda Pharmaceuticals is riding a ...

The FDA OKs pill schizophrenia and bipolar disorder treatment with Bysanti, a new atypical antipsychotic approved for adults.

Milsaperidone, a new chemical entity, is the major active metabolite of iloperidone (Fanapt) and had been demonstrated to be bioequivalent to iloperidone.

The biopharmaceutical company said Friday Bysanti tablets were approved for the acute treatment of manic or mixed episodes associated with bipolar I disorder, as well as for the treatment of ...

The FDA has set a Feb. 21 target decision on the Bysanti NDA. ・Vanda submitted the NDA in March 2025 for Bysanti to treat acute bipolar I disorder and schizophrenia. ・In May, the FDA said the ...

The company expects the Bysanti drug to be available in the market in the third quarter of 2026. ・The drug is being tested as ...

THESSALONIKI, Greece, 11 February 2025 - In a notable Genomic Press research report, researchers at the Aristotle University of Thessaloniki have uncovered a significant presence of manic symptoms in ...

Please provide your email address to receive an email when new articles are posted on . More than 16,000 twins were asked about psychedelic use and psychotic and manic symptoms. Data showed a strong ...